Quantum Genomics has announced the signing of an exclusive license agreement with Teva Israel Ltd. ? a subsidiary of Teva Pharmaceutical Industries Ltd. to market firibastat in Israel. A global pharmaceutical company founded and headquartered in Israel, Teva will receive exclusive marketing, selling and distribution rights for resistant and difficult-to-treat hypertension in its home market. Quantum Genomics will receive payments of up to $11 Million and 25% minimum up to 30% royalties on future firibastat sales.